Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Ader (lopinavir/ritonavir)
  NCT04315948		 RCTlopinavir/ritonavirCOVID 19 hospitalizedsome concern
-/- ongoing
    Nojomi
          IRCT20180725040596N2    		 RCTlopinavir/ritonavirumifenovir (arbidol)COVID 19 hospitalizedsome concern
    		50/50 inconclusive
      RECOVERY
              NCT04381936      		 RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
      		1616/3424 inconclusive
      • inconclusive 3 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
      the trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm
      SOLIDARITY (lopi/rito)
              NCT04315948      		 RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
      		1399/1372 inconclusive
      • inconclusive 0 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias

      COVID-19 mild to moderate meta-analysis

      ELACOI (lopinavir/ritonavir)
              NCT04252885      		 RCTlopinavir/ritonavirstandard of careCOVID-19 mild to moderatesome concern
      		21/7 inconclusive

        COVID-19 severe or critically meta-analysis

        Cao
                  ChiCTR2000029308        		 RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
        		99/100 suggested
        • inconclusive 31 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        • suggested 94 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
        REMAP-CAP (lopinavir/ritonavir only)
                  NCT02735707        		 RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
        		268/377 safety concern
        • statistically significant 17 % decrease in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
        1 study excluded by filtering options (0 RCT / 1 OBS)

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

         

        - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons